Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Sale of Southampton property

2nd Mar 2015 07:00

RNS Number : 1670G
Advanced Oncotherapy PLC
02 March 2015
 

2 March 2015

Advanced Oncotherapy plc

("AVO" or the "Company")

 

Sale of Southampton property

 

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for treating cancer, announces that the sale of the facility owned by the Company in Southampton has been completed. The site is a former GP surgery that the Company took beneficial ownership of previously. The net cash realised on the sale price of £290,000 will be used for development of the LIGHT proton therapy system.

 

Following this sale, there is a property in Folkestone left to dispose of which will almost complete the strategy of focusing solely on the development and delivery of our LIGHT system. The Company is also looking at strategic options for Oncotherapy Resources Ltd (ORL), its subsidiary focused on distributing an innovative brachytherapy device.

 

Sanjeev Pandya, CEO of Advanced Oncotherapy, said: "We are very pleased to have successfully marketed and sold this property. This almost completes the move away from the original business's history of property investment and ownership and provides useful extra cash for the development of the LIGHT system."

 

Advanced Oncotherapy Plc

www.avoplc.com

Sanjeev Pandya, CEO

Tel: +44 20 3617 8728

Nicolas Serandour, CFO

 

 

Westhouse Securities (Nomad & Joint Broker)

Tel: +44 20 7601 6100

Antonio Bossi / David Coaten

 

 

 

Beaufort Securities (Joint Broker)

Tel: +44 20 7382 8300

Saif Janjua / Jon Levinson

 

 

 

Walbrook PR (Financial PR & IR)

Tel: +44 20 7933 8780 or [email protected]

Paul McManus / Anna Dunphy

Mob: +44 7980 541 893 / Mob: +44 7876 741 001

 

About Advanced Oncotherapy Plc www.avoplc.com

 

Advanced Oncotherapy's team based at CERN in Geneva focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.

 

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. As a result, Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

 

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DISPGUPWPUPAGRM

Related Shares:

AVO.L
FTSE 100 Latest
Value8,868.34
Change-16.58